Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Olema Pharmaceuticals, Inc. (OLMA)

Olema Names Jason O'Byrne Chief Financial Officer, Effective August 11, 2026

Neutral Impact 4 of 5 leadership Written later

Olema Pharmaceuticals announced on August 13, 2026 that Jason O'Byrne has been appointed Chief Financial Officer, principal financial officer and principal accounting officer, effective August 11, 2026. He most recently served as Executive Vice President and Chief Financial Officer of Vir Biotechnology from October 2024 to August 2026. The filing sets his pay, including a $545,000 initial base salary and an option for 650,000 shares that is subject to Board approval.

Key points

  • Initial annualized base salary of $545,000 and an annual bonus target of 45% of base salary
  • Sign-on bonuses of $250,000 (within 30 days of the effective date) and $100,000 (within 30 days after the first anniversary), subject to service-based repayment
  • Option for 650,000 common shares under the 2022 Inducement Plan, vesting over four years, subject to Board approval
  • Severance includes 12 months of base salary; double-trigger protection applies if termination occurs within 3 months before or 18 months after a Change in Control

The filing

CompanyOlema Pharmaceuticals, Inc. (OLMA)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:05 AM ET
Accession number0001193125-26-347853

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.